Complex cancer gene therapy in mice melanoma

被引:14
作者
Dietrich, A
Kraus, K
Brinckmann, U
Freidrich, T
Müller, A
Liebert, UG
Schönfelder, M
机构
[1] Clin Thorac Gen & Oncol Surg, D-04103 Leipzig, Germany
[2] Univ Leipzig, Inst Virol, D-04103 Leipzig, Germany
[3] Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany
关键词
melanoma; cancer; gene therapy; APC engineering; cytokine;
D O I
10.1007/s00423-002-0299-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: We investigated the effects of continuous cancer gene therapy, including APC engineering and local stimulation of the immune system in a mice melanoma model. Materials and methods: B 16 melanoma cells were injected into C57/B16 mice intradermally. The overlying dermis or the tumor were shot with different plasmids using a gene gun every 4th day starting 8 days after tumor implantation. Control groups were mice without any therapy or gene therapy as described above with the empty plasmid. Therapy was: group 1, IL-12 and IL-2; group 11, IFN-gamma/B7. 1; group 111, IFN-gamma/B7.1, IL-12, and IL-2. Results: The median survival time of all therapy groups was significantly enhanced. The longest median survival was in the IL-12/IL-2 group. Tumor growth was reduced in all therapy groups. Control groups suffered a higher rate of metastasis and had fewer inflammatory cells at the tumor site. Conclusions: Continuous therapy with the gene gun is easy to handle and shows good results. Therapy with genes for IL-12 and IL-2 was superior to that with additional IFN-gamma/B7.1 or IFN-gamma/B7.1 alone. APC engineering is clearly less sufficient in the case of the B 16 melanoma.
引用
收藏
页码:177 / 182
页数:6
相关论文
共 26 条
[1]
Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors [J].
Addison, CL ;
Bramson, JL ;
Hitt, MM ;
Muller, WJ ;
Gauldie, J ;
Graham, FL .
GENE THERAPY, 1998, 5 (10) :1400-1409
[2]
ALBERTI G, 1996, COMPREHENSIVE SUPRAM, V7, P1
[3]
Immunity to breast cancer in mice immunized with X-irradiated breast cancer cells modified to secrete IL-12 [J].
Carr-Brendel, V ;
Markovic, D ;
Smith, M ;
Taylor-Papadimitriou, JT ;
Cohen, EP .
JOURNAL OF IMMUNOTHERAPY, 1999, 22 (05) :415-422
[4]
INVIVO PROMOTER ACTIVITY AND TRANSGENE EXPRESSION IN MAMMALIAN SOMATIC TISSUES EVALUATED BY USING PARTICLE BOMBARDMENT [J].
CHENG, L ;
ZIEGELHOFFER, PR ;
YANG, NS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (10) :4455-4459
[5]
Active immunotherapy of pancreatic cancer with tumor cells genetically engineered to secrete multiple cytokines [J].
Clary, BM ;
Coveney, EC ;
Blazer, DG ;
Philip, R ;
Lyerly, HK .
SURGERY, 1996, 120 (02) :174-181
[6]
Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans [J].
Decken, K ;
Köhler, G ;
Palmer-Lehmann, K ;
Wunderlin, A ;
Mattner, F ;
Magram, J ;
Gately, MK ;
Alber, G .
INFECTION AND IMMUNITY, 1998, 66 (10) :4994-5000
[7]
HIURA M, 1994, FOLIA BIOL-PRAGUE, V40, P49
[8]
KATSANIS E, 1995, CANCER GENE THER, V2, P39
[9]
KRAUS K, 2002, THESIS LEIPZIG U
[10]
Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1+-matched situation [J].
Meyer, GC ;
Batrla, R ;
Rudy, W ;
Meuer, SC ;
Wallwiener, D ;
Gückel, B ;
Moebius, U .
CANCER GENE THERAPY, 1999, 6 (03) :282-288